RESOURCES > Federal Register Notices > Rules - 2022
Rules - 2022
Drug Scheduling Actions
Final Rule: Placement of Serdexmethylphenidate in Schedule IV (PDF) (June 24, 2022)
Final Rule: Placement of Methoxetamine (MXE) in Schedule I (PDF) (June 6, 2022)
Interim Final Rule: Placement of Ganaxolone in Schedule V (PDF) (June 1, 2022)
Final Rule: Requiring Online Submission of Applications for and Renewals of DEA Registration (PDF) (April 11, 2022)
Interim Final Rule: Placement of Daridorexant in Schedule IV (PDF) (April 7, 2022)
Final Rule: Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I (PDF) (April 7, 2022)
Exempt Chemical Preparations under the Controlled Substances Act
Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (April 19, 2022)
Exempt Chemical Preparations Under the Controlled Substances Act; Correction (PDF) (February 3, 2022)
Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (January 21, 2022)
Proposed Rules
Proposed Rule: Exempted Prescription Products (PDF) (April 12, 2022)
Proposed Rule: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (PDF) (April 11, 2022)
NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).